ClinicaliQ Trial Snapshot
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA — Recruiting • Phase II • Cardiology / Cardiovascular • NCT06868290.
- What is being tested: Rapcabtagene autoleucel, a CAR-T cell therapy, is being evaluated for efficacy and safety in treating severe active GPA (Granulomatosis with Polyangiitis) or MPA (Microscopic Polyangiitis), compared against a comparator treatment in a Phase 2 trial.
- Patient eligibility overview: The study enrolls participants with severe active GPA or MPA; specific eligibility criteria would typically include confirmed diagnosis, active disease requiring treatment, and absence of significant comorbidities that would preclude CAR-T cell therapy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Eligibility Snapshot
- Key inclusion criteria: 1. Men and women, aged ≥18 and ≤ 75 years with a diagnosis of GPA or MPA according to the American College of Rheumatology/ European League Against Rheumatism 2022 (ACR/EULAR 2022) classification criteria 2. Positive test for ANCA-autoantibodies 3. GPA and MPA participants with severe active disease Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.